JAK2 and essential thrombocythemia: In 2005 four groups including that of Tony Green in Cambridge described the JAK2 V617F mutation in most patients with polycythaemia vera and about half those with essential thrombocythaemia (ET) and myelofibrosis (MF) (reviewed by Campbell and Green [76]).